← Back to Screener
Esperion Therapeutics, Inc. (ESPR)
Price$2.02
Favorite Metrics
Price vs S&P 500 (26W)-32.62%
Price vs S&P 500 (4W)-31.04%
Market Capitalization$510.15M
All Metrics
Book Value / Share (Quarterly)$0.32
P/TBV (Annual)82.30x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)74.78%
Cash Flow / Share (Quarterly)$-0.05
Price vs S&P 500 (YTD)-49.34%
Gross Margin (TTM)67.95%
Net Profit Margin (TTM)-5.63%
EPS (TTM)$-0.17
10-Day Avg Trading Volume8.30M
EPS Excl Extra (TTM)$-0.17
Revenue Growth (5Y)12.12%
EPS (Annual)$-0.11
ROI (Annual)-486.00%
Gross Margin (Annual)67.95%
Net Profit Margin (5Y Avg)-170.77%
Cash / Share (Quarterly)$0.68
Revenue Growth QoQ (YoY)143.73%
ROA (Last FY)-4.87%
Revenue Growth TTM (YoY)21.31%
EBITD / Share (TTM)$0.29
ROE (5Y Avg)-171.90%
Operating Margin (TTM)14.95%
Cash Flow / Share (Annual)$-0.05
P/B Ratio56.68x
P/B Ratio (Quarterly)114.92x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)2.20x
Net Interest Coverage (TTM)0.74x
ROA (TTM)-6.04%
EV / EBITDA (TTM)14.70x
EPS Incl Extra (Annual)$-0.11
Current Ratio (Annual)1.54x
Quick Ratio (Quarterly)1.02x
3-Month Avg Trading Volume5.45M
52-Week Price Return112.63%
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$0.32
P/S Ratio (Annual)1.27x
Asset Turnover (Annual)0.87x
52-Week High$4.17
Operating Margin (5Y Avg)-129.17%
EPS Excl Extra (Annual)$-0.11
CapEx CAGR (5Y)-19.71%
Tangible BV CAGR (5Y)-31.73%
26-Week Price Return-25.74%
Quick Ratio (Annual)1.02x
13-Week Price Return-35.46%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)1.54x
Enterprise Value$887.547
Revenue / Share Growth (5Y)-25.18%
Asset Turnover (TTM)1.07x
Book Value / Share Growth (5Y)-35.70%
Revenue / Employee (Annual)$1
Inventory Turnover (Annual)1.29x
Pretax Margin (Annual)-5.17%
Cash / Share (Annual)$0.68
3-Month Return Std Dev72.43%
Gross Margin (5Y Avg)71.25%
Net Income / Employee (TTM)$-0
ROE (Last FY)-486.00%
Net Interest Coverage (Annual)0.74x
EPS Basic Excl Extra (Annual)$-0.11
P/FCF (TTM)11.28x
Receivables Turnover (TTM)3.66x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.17
Receivables Turnover (Annual)3.66x
ROI (TTM)-59.48%
P/S Ratio (TTM)1.27x
Pretax Margin (5Y Avg)-170.68%
Revenue / Share (Annual)$1.94
Tangible BV / Share (Annual)$0.72
Forward P/E45.50x
Price vs S&P 500 (52W)78.00%
Year-to-Date Return-45.41%
5-Day Price Return-1.46%
EPS Normalized (Annual)$-0.11
ROA (5Y Avg)-57.28%
Net Profit Margin (Annual)-5.63%
Month-to-Date Return-26.28%
Cash Flow / Share (TTM)$-2.23
EBITD / Share (Annual)$0.29
Operating Margin (Annual)14.95%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-171.72%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.17
P/TBV (Quarterly)116.21x
P/B Ratio (Annual)81.89x
Inventory Turnover (TTM)1.29x
Pretax Margin (TTM)-5.17%
Book Value / Share (Annual)$0.72
Price vs S&P 500 (13W)-37.84%
Beta0.98x
Revenue / Share (TTM)$1.70
ROE (TTM)-59.48%
52-Week Low$0.69
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
3.93
3.93
3.93
3.93
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
ESPREsperion Therapeutics, Inc. | 1.27x | 21.31% | 67.95% | — | $2.02 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Esperion Therapeutics develops and commercializes oral, once-daily non-statin therapies for patients with elevated LDL cholesterol. The company's portfolio includes NEXLETOL, NEXLIZET, NILEMDO, and NUSTENDI, providing accessible alternatives to traditional statins. Esperion focuses on addressing the significant patient population requiring innovative lipid management solutions.